Answers are grounded in this paper and cite their sources.
Study formulates and optimizes solid-lipid nanoparticles of inavolisib for breast cancer therapy, indicating promising developments in drug delivery.
ABSTRACTBreast cancer is one of the most prevalent and life-threatening malignancies affecting womenworldwide and remains a major public health concern due to its increasing incidence, highmortality rate, and limitations associated with conventional chemotherapy. The currentlyavailable therapeutic approaches for breast cancer treatment often suffer from poorselectivity, systemic toxicity, multidrug resistance, and inadequate drug concentration at thetumor site, which significantly reduce therapeutic efficacy and patient compliance. In recentyears, nanotechnology-based drug delivery systems have emerged as promising strategies forimproving the therapeutic performance of anticancer agents. Inavolisib is a novelphosphoinositide 3-kinase alpha (PI3Kα) inhibitor developed for the treatment of hormonereceptor-positive and HER2-negative breast cancer associated with PIK3CA mutations.Although Inavolisib has shown promising anticancer activity, its therapeutic potential islimited due to poor aqueous solubility, low oral bioavailability, rapid metabolism, andpossible systemic adverse effects.
No takes yet. Share an insight, caveat, or question.
Vaibhav Bidve, Dr. Pramod M. Bhosale, Dr. Vitthal G. Kuchake (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: